Flurazepam Hydrochloride
A hydrochloride salt form of flurazepam, a benzodiazepine used to treat short-term insomnia by enhancing inhibitory signaling in the brain to promote sleep. This salt form improves the drug's solubility for oral administration. Patients should be aware of the risk of tolerance, dependence, and next-day sedation.
分子量
460.8000 g/mol
TPSA
35.90 Ų
治療領域
作用機序
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …
2D構造
Cite this structure
Embed this structure
SMILES
CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl
InChI
InChI=1S/C21H23ClFN3O.2ClH/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23;;/h5-10,13H,3-4,11-12,14H2,1-2H3;2*1H
Molecular Formula
C21H25Cl3FN3O
HBD / HBA
2 / 4
回転可能結合数
6
重原子数
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A hydrochloride salt form of flurazepam, a benzodiazepine used to treat short-term insomnia by enhancing inhibitory signaling in the brain to promote sleep. This salt form improves the drug's solubility for oral administration. Patients should be aware of the risk of tolerance, dependence, and next-day sedation.
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Yes, Flurazepam Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989724. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 14434. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="flurazepam-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/flurazepam-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/flurazepam-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/flurazepam-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="flurazepam-hydrochloride"></drugfyi-drug>